Levodopa/Carbidopa/Entacapone Eg (Carbidopa, Entacapone, Levodopa)

Levodopa/Carbidopa/Entacapone is used within the antiparkinson therapeutic class to manage motor symptoms of Parkinson's disease and related fluctuations.

• Parkinson's disease: improves overall motor function and reduces rigidity and bradykinesia.
• Parkinson's disease with motor fluctuations: prolongs the duration of levodopa effect and lessens OFF periods.
• Adjunct therapy in early Parkinson's disease: enhances central dopaminergic activity when levodopa alone is insufficient.

• Levodopa is converted to dopamine in the brain, providing the deficient neurotransmitter in Parkinson's disease. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, preventing levodopa’s conversion outside the central nervous system and increasing its availability to the brain. Entacapone blocks catechol‑O‑methyltransferase (COMT), slowing levodopa metabolism, extending its plasma half‑life, and sustaining dopaminergic stimulation.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Dizziness: often related to orthostatic changes.
• Headache: transient and usually self‑limiting.
• Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

• Dyskinesia: involuntary, erratic movements.
• Hallucinations: visual or auditory perceptual disturbances.
• Severe hypotension: marked drop in blood pressure with risk of fainting.
• Neuroleptic malignant syndrome: rare but life‑threatening reaction.
• Anaphylaxis: acute allergic response requiring immediate medical attention.

Levodopa/Carbidopa/Entacapone requires careful monitoring to ensure safe use.

• Blood pressure monitoring: watch for orthostatic hypotension, especially during dose titration.
• Psychiatric assessment: observe for hallucinations, confusion, or mood changes.
• Renal function evaluation: adjust therapy in patients with significant renal impairment.
• Discontinuation caution: avoid abrupt cessation to prevent withdrawal or worsening of symptoms.
• Elderly patients: start at low dose and titrate slowly due to increased sensitivity.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone can interact with several drug classes.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: risk of hypertensive crisis.
• Selective MAO‑B inhibitors (e.g., selegiline): may cause severe hypertension.
• Antipsychotics with strong dopamine blockade (e.g., haloperidol): reduce therapeutic effect.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: additive blood‑pressure lowering effect.
• SSRIs and SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors.
• Iron or antacid supplements: may decrease levodopa absorption; separate dosing by at least 2 hours.